Did you know that you can buy products from over 140 different suppliers from us?

Apolipoprotein C-III (APOC3) ELISA Kit

Details for Product No. ABIN612668
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Target Name (Antigen)
Synonyms APOC3, APOCIII, HALP2, Apoc, ApoC-III, apo-CIII, Apo-CIII
Reactivity
Alternatives Human
Kits with alternative reactivity to:
(2), (3), (2), (1), (2), (7), (2), (7), (4), (2), (7), (1)
Methode Type Sandwich ELISA
Minimum Detection Limit 5 ng/mL
Application
ELISA
Pubmed 11 references available
Quantity 96 tests
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days
Catalog No. ABIN612668
407.00 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Purpose The AssayMax Human Apo C-III ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for detection of human Apo C-III in plasma, serum, urine, and cell culture samples
Sample Type Plasma, Cell Culture Supernatant
Detection Method Colorimetric
Cross-Reactivity Dog (Canine), Cow (Bovine), Monkey, Mouse (Murine), Rat (Rattus), Pig (Porcine)
Cross-Reactivity (Details) No significant cross reactivity with Apo AI, Apo AII, Apo B, Apo CI, Apo CII, or Apo E.
Components Human Apo C-III Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human Apo C-III. Sealing Tapes: Each kit contains 3 pre-cut, pressure-sensitive sealing tapes that can be cut to fit the format of the individual assay. 1 Human Apo C-III Standard: Human Apo C-III in a buffered protein base (8 µg, lyophilized). Biotinylated Apo C-III Antibody (100x): A 100-fold concentrated biotinylated polyclonal antibody against Apo C-III (80µl). EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml). Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles). Streptavidin-Peroxidase Conjugate (SP Conjugate): A 100-fold concentrate (90µl). Chromogen Substrate: A ready-to-use stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml). Stop Solution: A 0.5 N hydrochloric acid to stop the chromogen substrate reaction (12 ml).
Material not included Microplate reader capable of measuring absorbance at 450 nm. Pipettes (1-20 µL, 20-200 µL, 200-1000µLand multiple channel). Deionized or distilled reagent grade water
Alternative Name Apolipoprotein C-III
Background Apolipoprotein C-III (apoC-III) is a surface component of chylomicrons, very low density lipoproteins, and high density lipoproteins. It consists of 79 amino acids with a molecular mass of 8.8 kDa. ApoC-III is synthesized mainly in the liver and to a lesser degree in the intestine. It plays a key role in triglyceride-rich lipoprotein metabolism. It is an inhibitor of lipoprotein lipase and hepatic lipase, and interferes with binding of lipoproteins to cell surface heparan sulfate proteoglycans and receptors (2 -3). Overexpression of the human apoC-III gene causes hypertriglyceridemia in transgenic mice (4 - 5). Deficiency of apoC-III prevents hyperlipidemia induced by apoE overexpression. As its deficiency results in diet-induced obesity and aggravated insulin resistance in mice, apoC3 is a potential target for treatment of obesity and insulin resistance.
Research Area Metabolism
Sample Volume 50 µL
Assay Time < 4 h
Plate Pre-coated,Strips (12 x 8)
Protocol This assay employs a quantitative sandwich enzyme immunoassay technique that measures human Apo C-III in less than 4 hours. A polyclonal antibody specific for human Apo C-III has been pre-coated onto a 96-well microplate with removable strips. Apo C-III in standards and samples is sandwiched by the immobilized antibody and biotinylated polyclonal antibody specific for Apo C-III, which is recognized by a streptavidin-peroxidase conjugate. All unbound material is then washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.
Reagent Preparation Freshly dilute all reagents and bring all reagents to room temperature before use. If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. 2 EIA Diluent Concentrate (10x): Dilute the EIA Diluent 1:10 with reagent grade water. Store for up to 1 month at 2-8°C. Standard Curve: Reconstitute the 8 g of Apo CIII standard with 4 ml of EIA Diluent to generate a stock solution of 2 g/ml. Allow the standard to warm to room temperature prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting the standard solution (2 g /ml) 1:4 with EIA Diluent to produce 0.5, 0.125, 0.0313 and 0.0078 g/ml solutions. EIA Diluent serves as the zero standard (0 g/ml). Any remaining solution should be frozen at -20°C. Standard Point Dilution [Apo C-III] ( g/ml) Standard (2 g/ml) P1 2.0000 P2 1 part P1 + 3 part EIA Diluent 0.5000 P3 1 part P2 + 3 part EIA Diluent 0.1250 P4 1 part P3 + 3 part EIA Diluent 0.0313 P5 1 part P4 + 3 part EIA Diluent 0.0078 P6 EIA Diluent 0.0000 Biotin Apo C-III Antibody (100x): Spin down the antibody briefly and dilute the desired amount of the antibody 1:100 with EIA Diluent. Any remaining solution should be frozen at -20°C. Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 1:20 with reagent grade water. SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 1:100 with EIA Diluent. Any remaining solution should be frozen at -20°C.
Sample Collection Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 2000 x g for 10 minutes and assay. Dilute samples 1:500 into EIA Diluent as follows: add 10 µl of sample to 490 µl of EIA Diluent (1:50) to make Solution A, then add 80 µl of Solution A to 720 µl of EIA Diluent (1:10) to make a final working solution (1:500). Store samples at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles. (EDTA can also be used as anticoagulant) Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 2000 x g for 10 minutes. Dilute samples 1:500 into EIA Diluent as follows: add 10 µl of sample to 490 µl of EIA Diluent (1:50) to make Solution A, then add 80 µl of Solution A to 720 µl of EIA Diluent (1:10) to make a final working solution (1:500). Store samples at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles. Cell Culture Supernatants: Centrifuge cell culture media at 2000 x g for 10 minutes to remove debris. Collect supernatants and assay. Store samples at -20°C or below. Avoid repeated freeze-thaw cycles. Urine: Collect urine using sample pot. Centrifuge samples at 800 x g for 10 minutes and assay. Store samples at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
Assay Procedure Prepare all reagents, working standards and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20 - 30 °C). Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccant inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator. Add 50 µL of Apo C-III standard or sample per well. Cover wells with a sealing tape and incubate for two hours. Start the timer after the last sample addition. Wash five times with 200 µL of Wash Buffer manually. Invert the plate each time and decant the contents, hit it 4-5 times on absorbent paper towel to completely remove the liquid. If using a machine wash six times with 300 µL of Wash Buffer and then invert the plate, decant the contents, hit it 4-5 times on absorbent paper towel to completely remove the liquid. Add 50 µL of Biotinylated Apo C-III Antibody to each well and incubate for one hour. Wash a microplate as described above. Add 50 µL of Streptavidin-Peroxidase Conjugate to each well and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance. Wash a microplate as described above. Add 50 µL of Chromogen Substrate per well and incubate for about 15 minutes or till the optimal blue color density develops. Gently tap plate to ensure thorough mixing and break the bubbles in the well with pipette tip. Add 50 µL of Stop Solution to each well. The color will change from blue to yellow. Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.
Calculation of Results Calculate the mean value of the duplicate or triplicate readings for each standard and sample. To generate a Standard Curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The best-fit line can be determined by regression analysis using log-log or four-parameter logistic curve-fit. Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor. Standard Curve The curve is used for illustration only. A standard curve should be generated each time the assay is performed.
Assay Precision Intra-assay and inter-assay coefficients of variation were 4.8 % and 7.3 % respectively.
Restrictions For Research Use only
Handling Advice The kit should not be used beyond the expiration date.
Storage 4 °C/-20 °C
Storage Comment Store kit at 2-8°C or -20°C upon arrival up to the expiration date. Opened EIA Diluent may be stored for up to 1 month at 2-8°C. Store reconstituted reagents at -20°C or below. Opened unused strip wells may return to the foil pouch with the desiccant pack, reseal along zip-seal. May be stored for up to 1 month in a vacuum desiccator.
Product cited in: Grant, ODell, Karl et al.: "Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice." in: Science (New York, N.Y.), Vol. 258, Issue 5090, pp. 1903-10, 1993 (PubMed).

Ito, Azrolan, OConnell et al.: "Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice." in: Science (New York, N.Y.), Vol. 249, Issue 4970, pp. 790-3, 1990 (PubMed).

Cooke, Perlmutter: "Expression of a novel form of the fyn proto-oncogene in hematopoietic cells." in: The New biologist, Vol. 1, Issue 1, pp. 66-74, 1991 (PubMed).

Kawakami, Kawakami, Aaronson et al.: "Acquisition of transforming properties by FYN, a normal SRC-related human gene." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 85, Issue 11, pp. 3870-4, 1988 (PubMed).

Wang, McConathy, Kloer et al.: "Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III." in: The Journal of clinical investigation, Vol. 75, Issue 2, pp. 384-90, 1985 (PubMed).

Dammerman, Sandkuijl, Halaas et al.: "An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, Issue 10, pp. 4562-6, 1993 (PubMed).

Aalto-Setälä, Weinstock, Bisgaier et al.: "Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice." in: Journal of lipid research, Vol. 37, Issue 8, pp. 1802-11, 1997 (PubMed).

Jong, Hofker, Havekes: "Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3." in: Arteriosclerosis, thrombosis, and vascular biology, Vol. 19, Issue 3, pp. 472-84, 1999 (PubMed).

Duivenvoorden, Teusink, Rensen et al.: "Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice." in: Diabetes, Vol. 54, Issue 3, pp. 664-71, 2005 (PubMed).

Gerritsen, Rensen, Kypreos et al.: "ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression." in: Journal of lipid research, Vol. 46, Issue 7, pp. 1466-73, 2005 (PubMed).

Matikainen, Taskinen: "The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes." in: Diabetic medicine : a journal of the British Diabetic Association, 2012 (PubMed).

Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN612668
407.00 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Validation Images
Did you look for something else?
back to top